Converge Bio secures $2.5M Gates Foundation grant to extend AI drug discovery into crop genomics
What's the deal? Converge Bio, a Boston and Tel Aviv-based generative AI lab for life sciences, has secured US$1.62M multi-year grant from the Gates FoundationDealroom has a profile for this one. Try Dealroom → to extend its drug discovery platform into crop genomics. The initiative will develop a foundation model that identifies genetic variants linked to crop yield and climate resilience, targeting smallholder farmers in sub-Saharan Africa and South Asia.
The 37-month grant marks Converge Bio's first move from human health into agriculture. Founded in 2024, the 40-person startup builds AI platforms that help biotech and pharma companies accelerate drug discovery.
Why now? Traditional crop breeding takes 12 to 15 years to produce a new variety — far too slow for a climate that's shifting faster than agriculture can adapt. Crop genomes are among the most complex systems in biology, and isolating the specific genetic features that make plants resilient remains painstaking work.
Converge Bio's AI-powered "virtual cell" approach treats the genome as an interconnected system rather than a collection of parts. Much like a large language model processing an entire document, it analyses millions of base pairs simultaneously to rank which genes or mutations most likely drive a specific outcome — and shows which parts of the DNA informed those predictions.
What could go wrong? Translating a platform built for pharma into agricultural genomics is not straightforward. Crop genomes are often far larger and more repetitive than human genomes, and lab-identified targets still need real-world validation through breeding trials. The startup must also prove its models work across diverse crops and growing conditions relevant to smallholder farmers.
The signal: Converge Bio's pivot from pharma to agriculture illustrates a growing pattern of breakout-stage AI drug discovery startups repurposing their platforms for adjacent sectors under climate pressure. The Gates Foundation grant also underscores how philanthropic capital is stepping in to fund AI-for-agriculture bets where traditional venture investment remains thin, particularly for use cases targeting smallholder farmers with limited commercial upside in the near term.
Read more: PR Newswire
